255 related articles for article (PubMed ID: 34125992)
21. Clinical and Molecular Attributes of Patients With BCR/ABL1-negative Myeloproliferative Neoplasms in India: Real-world Data and Challenges.
Singh S; Kaur K; Paul D; Jain K; Singh J; Narang V; Garg B; Sood N; Dhillon B
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e569-e578. PubMed ID: 33757770
[TBL] [Abstract][Full Text] [Related]
22. A rapid, highly accurate method for quantifying CALR mutant allele burden in persons with myeloproliferative neoplasms.
Yao QM; Zhou J; Gale RP; Li JL; Li LD; Li N; Chen SS; Ruan GR
Hematology; 2015 Oct; 20(9):517-22. PubMed ID: 25860380
[TBL] [Abstract][Full Text] [Related]
23. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
Ha JS; Kim YK
Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
[TBL] [Abstract][Full Text] [Related]
24. RAPID LOW-COST DETECTION OF TYPE 2CALR MUTATION BY ALLELE-SPECIFIC RT-PCR FOR DIAGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS.
Dybkov MV; Zavelevich MP; Gluzman DF; Telegeev GD
Exp Oncol; 2022 May; 44(1):83-86. PubMed ID: 35548965
[TBL] [Abstract][Full Text] [Related]
25. The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
Labastida-Mercado N; Galindo-Becerra S; Garcés-Eisele J; Colunga-Pedraza P; Guzman-Olvera V; Reyes-Nuñez V; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
Hematol Oncol Stem Cell Ther; 2015 Mar; 8(1):16-21. PubMed ID: 25637689
[TBL] [Abstract][Full Text] [Related]
26. Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia.
Kang MG; Choi HW; Lee JH; Choi YJ; Choi HJ; Shin JH; Suh SP; Szardenings M; Kim HR; Shin MG
Oncotarget; 2016 Aug; 7(35):57036-57049. PubMed ID: 27486987
[TBL] [Abstract][Full Text] [Related]
27. CALR mutations screening in wild type JAK2(V617F) and MPL(W515K/L) Brazilian myeloproliferative neoplasm patients.
Nunes DP; Lima LT; Chauffaille Mde L; Mitne-Neto M; Santos MT; Cliquet MG; Guerra-Shinohara EM
Blood Cells Mol Dis; 2015 Oct; 55(3):236-40. PubMed ID: 26227853
[TBL] [Abstract][Full Text] [Related]
28. Validation of a molecular diagnostic assay for CALR exon 9 indels in myeloproliferative neoplasms: identification of coexisting JAK2 and CALR mutations and a novel 9 bp deletion in CALR.
Murugesan G; Guenther-Johnson J; Mularo F; Cook JR; Daly TM
Int J Lab Hematol; 2016 Jun; 38(3):284-97. PubMed ID: 27018326
[TBL] [Abstract][Full Text] [Related]
29. CALR gene mutational profile in myeloproliferative neoplasms with non-mutated JAK2 in Moroccan patients: A case series and germline in-frame deletion.
Smaili W; Doubaj Y; Laarabi FZ; Lyahyai J; Kerbout M; Mikdame M; Sefiani A
Curr Res Transl Med; 2017; 65(1):15-19. PubMed ID: 28340692
[TBL] [Abstract][Full Text] [Related]
30. MOLECULAR GENETIC ABNORMALITIES IN THE GENOME OF PATIENTS WITH Ph-NEGATIVE MYELOPROLIFERATIVE NEOPLASIA AFFECTED BY IONIZING RADIATION AS A RESULT OF THE CHORNOBYL NUCLEAR ACCIDENT.
Poluben LO; Neumerzhytska LV; Klymenko SV; Fraenkel P; Balk C; Shumeiko OO
Probl Radiac Med Radiobiol; 2020 Dec; 25():362-373. PubMed ID: 33361847
[TBL] [Abstract][Full Text] [Related]
31. Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
Frawley T; O'Brien CP; Conneally E; Vandenberghe E; Percy M; Langabeer SE; Haslam K
Genet Test Mol Biomarkers; 2018 Feb; 22(2):98-103. PubMed ID: 29323541
[TBL] [Abstract][Full Text] [Related]
32. Progenitor genotyping reveals a complex clonal architecture in a subset of CALR-mutated myeloproliferative neoplasms.
Martin S; Wright CM; Scott LM
Br J Haematol; 2017 Apr; 177(1):55-66. PubMed ID: 28168700
[TBL] [Abstract][Full Text] [Related]
33. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
Chen Y; Fang F; Hu Y; Liu Q; Bu D; Tan M; Wu L; Zhu P
PLoS One; 2016; 11(4):e0154183. PubMed ID: 27111338
[TBL] [Abstract][Full Text] [Related]
34. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms.
Tefferi A; Thiele J; Vannucchi AM; Barbui T
Leukemia; 2014 Jul; 28(7):1407-13. PubMed ID: 24441292
[TBL] [Abstract][Full Text] [Related]
35. CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms.
Belcic Mikic T; Pajic T; Sever M
Sci Rep; 2019 Dec; 9(1):19838. PubMed ID: 31882869
[TBL] [Abstract][Full Text] [Related]
36. JAK2/STAT5 Pathway Mutation Frequencies in South African BCR/ABL Negative MPN Patients.
Shires KL; Rust AJ; Harryparsad R; Coburn JA; Gopie RE
Hematol Oncol Stem Cell Ther; 2023 Apr; 16(3):291-302. PubMed ID: 37023224
[TBL] [Abstract][Full Text] [Related]
37. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
38. A Comparison of Two Molecular Methods for Detecting CALR Mutations in Myeloproliferative Neoplasms.
Chan TH; Wang YY; Chen CC; Huang WL; Lin IY; Er TK
Clin Lab; 2021 Sep; 67(9):. PubMed ID: 34542973
[TBL] [Abstract][Full Text] [Related]
39. A novel assay to detect calreticulin mutations in myeloproliferative neoplasms.
Rosso V; Petiti J; Bracco E; Pedrola R; Carnuccio F; Signorino E; Carturan S; Calabrese C; Bot-Sartor G; Ronconi M; Serra A; Saglio G; Frassoni F; Cilloni D
Oncotarget; 2017 Jan; 8(4):6399-6405. PubMed ID: 28031530
[TBL] [Abstract][Full Text] [Related]
40. [Clinical significance of JAK2、CALR and MPL gene mutations in 1 648 Philadelphia chromosome negative myeloproliferative neoplasms patients from a single center].
Li MY; Chao HY; Sun AN; Qiu HY; Jin ZM; Tang XW; Han Y; Fu CC; Chen SN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):295-300. PubMed ID: 28468090
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
